Evidence map›Paper›PMID 42767114›Full record

ArticleDrug and alcohol dependence2026

Higher prevalence of non-fatal overdose with opioid and stimulant use compared to use of opioids alone.

Lydia N Drumright, Kanna Hayashi, Shruti H Mehta, Mai T Pho, Kora DeBeck, Heidi M Crane, Becky L Genberg, Hannah Cooper, Sonia Napravnik, William Zule and 29 more

Abstract read
In one paragraph

Article in Drug and alcohol dependence, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

39 authors.

Lydia N DrumrightUniversity of Washington, Seattle, WA, United States. Electronic address: lnd23@uw.edu.
Kanna HayashiSimon Fraser University, Vancouver, BC, Canada.
Shruti H MehtaJohns Hopkins University, Baltimore, MD, United States.
Mai T PhoUniversity of Chicago, IL, United States.
Kora DeBeckSimon Fraser University, Vancouver, BC, Canada.
Heidi M CraneUniversity of Washington, Seattle, WA, United States.
Becky L GenbergJohns Hopkins University, Baltimore, MD, United States.
Hannah CooperUniversity of Kentucky, Lexington, KY, United States.
Sonia NapravnikUniversity of North Carolina, Chapel Hill, NC, United States.
William ZuleRTI International, Durham, NC, United States.
Kenneth H MayerFenway Health, Boston, MA, United States.
Thomas J StopkaTufts University School of Medicine, Boston, MA, United States.
Laura BamfordUniversity of California, San Diego, CA, United States.
William C MillerUniversity of North Carolina, Chapel Hill, NC, United States.
George YendewaCasewestern Reserve University, Cleveland, OH, United States.
Vivan F GoUniversity of North Carolina, Chapel Hill, NC, United States.
Greer BurkholderUniversity of Alabama, Birmingham, AL, United States.
P Todd KorthuisOregon Health and Sciences University, Portland, OR, United States.
Katerina ChristopoulosUniversity of California, San Francisco, CA, United States.
David W SealTulane University, New Orleans, LA, United States.
Judith FeinbergWest Virginia University, Morgantown, WV, United States.
Peter D FriedmannUniversity of Massachusetts, Baystate, Springfield, MA, United States.
Wing Yin MokBritish Columbia Centre on Substance Use, Vancouver, BC, Canada.
Oluwaseun Falade-NwuliaJohns Hopkins University, Baltimore, MD, United States.
Ryan P KyleUniversity of Washington, Seattle, WA, United States.
Gordon S SmithUniversity of Massachusetts, Baystate, Springfield, MA, United States.
Jeanne C KerulyJohns Hopkins University, Baltimore, MD, United States.
Rob J FredericksenUniversity of Washington, Seattle, WA, United States.
Andrew W HahnUniversity of Washington, Seattle, WA, United States.
Bridget M WhitneyUniversity of Washington, Seattle, WA, United States.
L Sarah MixsonUniversity of Washington, Seattle, WA, United States.
Raul N MandlerNational Institute on Drug Abuse, North Bethesda, MD, United States.
Richard D MooreJohns Hopkins University, Baltimore, MD, United States.
Michael S SaagOregon Health and Sciences University, Portland, OR, United States.
M-J MilloyUniversity of British Columbia, Vancouver, BC, Canada.
Gregory D KirkJohns Hopkins University, Baltimore, MD, United States.
Joseph Ac DelaneyUniversity of Washington, Seattle, WA, United States.
Geetanjali ChanderUniversity of Washington, Seattle, WA, United States.
Judith I TsuiUniversity of Washington, Seattle, WA, United States.

Funding

University of Washington/Fred Hutch Center for AIDS ResearchP30AI027757 · NIAID · UNIVERSITY OF WASHINGTON · PI CONNIE L CELUM · 1988 to 2026
$104.9M
Unsolicited R24 for the CFAR-Network of Integrated Clinical Sciences, CNICSR24AI067039 · NIAID · UNIVERSITY OF ALABAMA AT BIRMINGHAM · PI Michael S. Saag · 2006 to 2026
$99.4M
Virology, Immunology, and Microbiology CoreP30AI050410 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI DAVID M. MARGOLIS · 2001 to 2026
$76.9M
The AIDS Linked to the Intravenous Experience (ALIVE) StudyU01DA036297 · NIDA · JOHNS HOPKINS UNIVERSITY · PI Gregory D Kirk, Shruti H Mehta · 2014 to 2026
$28.9M
Vancouver Drug Users Study: The Impacts of Evolving Drug Use Patterns on HIV/AIDSU01DA038886 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI DEBECK, KORA, HAYASHI, KANNA · 2015 to 2024
$12.1M
Alcohol Research Consortium in HIV: Relapse Prevention ArmP01AA029544 · NIAAA · JOHNS HOPKINS UNIVERSITY · PI HUTTON, HEIDI · 2021 to 2025
$7.1M
Ending transmission of HIV, HCV, and STDs and overdose in rural communities of people who inject drugs (ETHIC)UH3DA044829 · NIDA · UNIVERSITY OF CHICAGO · PI JENKINS, WILEY, PHO, MAI TUYET · 2019 to 2022
$5.2M
Substance use patterns and contexts: impact on epigenetic age and prevention strategies in an HIV clinical care cohortR01DA047045 · NIDA · UNIVERSITY OF WASHINGTON · PI Heidi M. Crane, Joseph Austin Delaney · 2018 to 2026
$5.1M
Scaling up HPTN 074: a Cluster Randomized Implementation Trial of an Evidence-based Intervention for Antiretroviral Therapy for PWID in VietnamR01DA047876 · NIDA · UNIV OF NORTH CAROLINA CHAPEL HILL · PI GO, VIVIAN F., MILLER, WILLIAM C · 2018 to 2022
$4.8M
Kentucky Communities and Researchers Engaging to Halt the Opioid Epidemic (CARE2HOPE)UH3DA044798 · NIDA · UNIVERSITY OF KENTUCKY · PI COOPER, HANNAH LF, YOUNG, APRIL MARIE · 2019 to 2022
$4.4M
Impacts of universal access to HIV/AIDS care among HIV+ injection drug usersU01DA021525 · NIDA · UNIVERSITY OF BRITISH COLUMBIA · PI MILLOY, M-J · 2017 to 2024
$4.3M
Oregon HIV/Hepatitis and Opioid Prevention and Engagement (OR-HOPE) Study Cost ExtensionUH3DA044831 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI KORTHUIS, PHILIP TODD · 2019 to 2022
$4.0M
NIAAA NIH HHS P01 AA029544NIAID NIH HHS K24 AI167805NIAID NIH HHS P30 AI027757NIAID NIH HHS P30 AI050410NIAID NIH HHS R24 AI067039NIDA NIH HHS F32 DA005830NIDA NIH HHS R01 DA047045NIDA NIH HHS R01 DA047876NIDA NIH HHS U01 DA021525NIDA NIH HHS U01 DA036297NIDA NIH HHS U01 DA038886NIDA NIH HHS U24 DA058307NIDA NIH HHS UG3 DA044825NIDA NIH HHS UH3 DA044798NIDA NIH HHS UH3 DA044823NIDA NIH HHS UH3 DA044826NIDA NIH HHS UH3 DA044829NIDA NIH HHS UH3 DA044830NIDA NIH HHS UH3 DA044831
6 · The paper itself

Abstract

backgroundFatalities from accidental drug overdose remain a major public health crisis in both the United States and Canada. Prior non-fatal overdose is an important risk factor for subsequent fatal overdose. Improved understanding of non-fatal overdose risk with respect to substance use patterns could support efforts to prevent overdose fatalities.

methodsWe examined associations between polydrug use and non-fatal overdose using data from four cohorts including people who use drugs (PWUD): ACCESS/VIDUS/ARYS (2018-2024), ALIVE (2018-2024), CNICS (2019-2025), and ROI (2018-2020). Cohorts collected data on drug use and non-fatal overdose in the past 6 months. Drug use was categorized as opioids only; opioids and stimulants; opioids and non-stimulant drugs; and non-opioid drugs. Relative risk regression models estimated prevalence ratios (PR) of nonfatal overdose by drug use adjusted for age, sex, race/ethnicity, and study time. Generalized estimating equations were used to examine repeated measures for ALIVE, CNICS, and ACCESS/VIDUS/ARYS. Random effects meta-analysis was used to obtain pooled estimates across cohorts.

resultsAmong 7573 people who use drugs (PWUD), mean age was 44.7 (SD+13.6) years; 71.4% were men, 60.8% reported White, 24.0% Black, and 7.1% Latine/Hispanic race/ethnicity; 44.1% had HIV; and 13.7% reported a non-fatal overdose at their last study visit. In pooled analyses, PWUD who reported using stimulants and opioids had greater non-fatal overdose prevalence, compared to opioids only (PR=2.26, 95% CI: 1.56-3.27). DISCUSSION: The higher prevalence of non-fatal overdose with opioids and stimulants compared to opioids alone across four diverse cohorts has implications for overdose prevention efforts.

Indexed as

Nonfatal overdoseOpioidsPolydrug useStimulants

Identifiers

PMID42767114
PMCPMC13629744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.